Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Proposed Swedish Pharma Pricing Model Suggests VBP Is Not Enough To Control Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

The new government directive on pricing and reimbursement leaves industry fearing that reference prices will be added to Sweden's value-based pricing system to cut costs.

You may also be interested in...



Sweden’s Reference Pricing Proposal: A Five-Year Doomsday Clock For Innovation?

Sweden may link its existing value-based pricing system with international reference pricing to cut drug expenditure, a move the pharmaceuticals industry says would devastate domestic R&D there.

European Generics Need To Climb Into Niches, Huddle Together For Growth

The current situation for Europe’s generic medicines manufacturers is at best uncomfortable due to significant pricing pressures and increasing competition, but the reality is that it is likely to get far worse.

German Pharmaceutical Law Removes Incentives For Orphan Drug R&D

National biotechnology and pharmaceutical industry associations object to certain provisions in the proposed German law on restructuring the pharma sector, AMNOG, that would add health technology assessments for orphan drugs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel